A prospective survey of Pseudomonas aeruginosa colonization and infection in the intensive care unit by Regev Cohen et al.
RESEARCH Open Access
A prospective survey of Pseudomonas
aeruginosa colonization and infection in the
intensive care unit
Regev Cohen1,2*, Frida Babushkin3, Shoshana Cohen3, Marina Afraimov3, Maurice Shapiro4, Martina Uda4,
Efrat Khabra5, Amos Adler5,6, Ronen Ben Ami6,7 and Svetlana Paikin8
Abstract
Background: Pseudomonas aeruginosa (PA) surveillance may improve empiric antimicrobial therapy, since
colonizing strains frequently cause infections. This colonization may be ‘endogenous’ or ‘exogenous’, and the
source determines infection control measures. We prospectively investigated the sources of PA, the clinical impact
of PA colonization upon admission and the dynamics of colonization at different body sites throughout the
intensive care unit stay.
Methods: Intensive care patients were screened on admission and weekly from the pharynx, endotracheal aspirate,
rectum and urine. Molecular typing was performed using Enterobacterial Repetitive Intergenic Consensus
Polymerase Chain reaction (ERIC-PCR).
Results: Between November 2014 and January 2015, 34 patients were included. Thirteen (38%) were colonized on
admission, and were at a higher risk for PA-related clinical infection (Hazard Ratio = 14.6, p = 0.0002). Strains were
often patient-specific, site-specific and site-persistent. Sixteen out of 17 (94%) clinical isolates were identical to
strains found concurrently or previously on screening cultures from the same patient, and none were unique.
Ventilator associated pneumonia-related strains were identical to endotracheal aspirates and pharynx screening
(87–75% of cases). No clinical case was found among patients with repeated negative screening.
Conclusion: PA origin in this non-outbreak setting was mainly ‘endogenous’ and PA-strains were generally patient-
and site-specific, especially in the gastrointestinal tract. While prediction of ventilator associated pneumonia-related
PA-strain by screening was fair, the negative predictive value of screening was very high.
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Background
Pseudomonas aeruginosa (PA) is a leading cause of
healthcare-associated infections in intensive care units
(ICUs), mainly ventilator-associated pneumonia (VAP),
central line-associated bloodstream infection (CLABSI)
and surgical site infection (SSI). PA colonization typically
precedes infection [1]. Colonization may be endogenous,
arising from the patient’s own microbial repertoire [2–4],
or exogenous if acquired from the hospital environment
or by cross-infection from other patients [5–11]. This
distinction has implications for the means needed for
infection control [12]. Specifically, water fixtures and
piping colonized with PA have been implicated as envir-
onmental reservoirs during outbreaks in ICUs [13, 14].
Use of point-of-care water filters was shown to effectively
reduce PA infections in surgical ICUs [4].
In previous work, we studied the genetic relatedness
of PA strains isolated from ventilated patients and
hospital faucets. We found a clear temporal and spatial
relation between patient and environmental strains [15].
In the present study we aimed to prospectively determine
the clinical impact of PA colonization on admission to the
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ICU and the dynamics of colonization at different body
sites throughout the ICU stay.
Methods
Study design
The study was conducted at the Sanz Medical Center, a
400-bed community hospital located in central Israel.
The adult ICU is a combined medical and surgical unit
with ~250 admissions (~2000 patient days) per year. The
ICU is located in one room with 6 beds with no physical
barrier between patients. ICU staff members were
instructed to use tap water for patients bathing only,
whereas sterile water was used for drinking, moistening
and mouth treatment. All faucet aerators were disman-
tled 23 months prior to initiation of this study [15].
All patients hospitalized in the ICU from November
2014 to January 2015 were included and underwent pro-
spective weekly PA surveillance cultures, as detailed
below. Patients staying in the unit for less than 72 h
were excluded from the analysis. The primary endpoint
was the development of clinical infection due to PA, de-
fined according to CDC/NHSN surveillance definitions
of healthcare-associated infections [16] and American
Thoracic Society criteria for VAP [17]. Secondary aims
were identifying risk factors for PA colonization on
admission and during ICU stay, clonal analysis of strains
at each body site during the ICU stay and the concord-
ance between the strains related to infection and those
detected on weekly screening.
This study was approved by the hospital institutional
review board committee (0033-14-LND). As the study
was aimed for infection control and patient safety pur-
poses, the requirement for informed consent was waived.
Clinical data
The following baseline characteristics were collected from
electronic medical records: age, sex, place of residence
(home or long-term care facility [LCTF]), comorbidities,
hospitalization within 90 days prior to admission, surgery
in the previous 30 days and duration of hospitalization
before admission to the ICU. We recorded the dates of
hospitalization, ICU admission and discharge, Acute
Physiology and Chronic Health Evaluation (APACHE) II
on ICU admission, length of stay in the ICU and in the
hospital in general, ventilation duration, tracheostomy
date, death in ICU and within 90 days of hospitalization
and major diagnoses in ICU. We also documented the
dates and sources of PA cultures (screening and clinical),
and PA related diagnoses of VAP, CLABSI, SSI and
catheter-associated urinary tract infection (CAUTI).
Surveillance cultures
Each patient was surveyed using standard bacterial
cultures on admission (within the first 72 h) and then
once a week until discharge. Cultures were collected using
swabs (Transsystem, Copan®, California, USA) from 4
sites: throat, rectum, endotracheal aspirate (EA) for venti-
lated patients, and urine, and transferred to the laboratory
within 30 min. Faucet cultures were collected weekly from
the distal part of the faucet using a bacterial swab.
Swabs were inoculated on tryptic soy blood agar,
chocolate agar, MacConkey agar and fluid thioglycoate
medium (Hy-labs®, Rehovot, Israel). Cultures were incu-
bated at 35° C overnight. Broth samples were subcul-
tured to the same media plates whenever no growth
was detected on the initial plates.
Bacterial identification and antimicrobial susceptibility
testing were done using the VITEK 2 system (Biomerieux,
Marcy l’Etoile, France) and interpreted according to CLSI
criteria [18].
PA isolates were stored at -70oc for molecular analysis.
Molecular typing was done by enterobacterial repetitive
intergenic consensus (ERIC)-PCR. DNA was extracted
using the easyMag® system (BioMerieux) and ERIC-PCR
was performed as previously described [19]. PCR products
were resolved using the QIAxcel capillary gel electrophor-
esis apparatus (QIAGEN, Hilden, Germany) [19]) and
compared visually. The discriminatory power of ERIC-
PCR was found to be similar to that of PFGE in PA [20].
Acquisition of PA was defined as the isolation of PA
from surveillance or clinical cultures from patients not
colonized within 72 h of admission. Colonization was
defined as the isolation of PA from specimens taken
from the rectum, catheter-urine, pharynx or EA, in the
absence of clinical infection.
Statistical analysis
Patient characteristics were presented using descrip-
tive statistics. Continuous variables were compared
using the Student t test or Mann Whitney test, and
two-tailed Fisher’s exact test was used for categorical
variables. Time to PA related infections was evaluated
with the Kaplan-Meier method, with the day of ICU
admission serving as day 0. Differences between
curves were calculated with the two-sided logrank
test. Death discharge from hospital, and PA related
infection were treated as competing events. In all




Sixty specimens were obtained from 6 faucets over
the study period. Of these, only 1 specimen (1.6%)
was positive for PA, and was found to be a unique
genotype.
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Patient surveillance cultures
Fifty-six patients were admitted to the ICU during the
study period. Eleven patients were excluded (5 hospital-
ized < 72h and 6 discharged prior to screening). Out of the
remaining 45 patients, 34 patients were screened <72h
from admission and 11 were screened ≥72h from admis-
sion. Four of the 11 patients screened late were found
negative and were regarded also as negative on admission,
and together comprised the study cohort of 38 pa-
tients (Fig. 1).
Of the 38 patients, 13 (34%) were colonized with PA on
admission (Table 1). Advanced age (>70 years) and resi-
dency in a LTCF were significantly associated with PA
colonization on admission (odds ratio (OR) 7, 95% confi-
dence interval (CI) 1.2-38.3; p = 0.035; OR = 17, 95% CI
0.8–358, p = 0.033, respectively; Table 1). Diabetes mellitus
was negatively associated with PA colonization (OR = 0.06,
95% CI 0.007–0.58; p = 0.005).
Of the 38 patients in the study cohort, 21 were still hos-
pitalized on the next week, and 11 (52%) of them screened
positive for PA (Table 2). The proportion of patients with
positive PA screening increased with length of ICU stay,
reaching 71% after 3 weeks of ICU stay (Table 2). Three
(12%) of 25 patients who were negative on admission
screening acquired PA during their ICU stay. In two of
them, PA was also found in clinical cultures of sputum,
and in one VAP was diagnosed.
Of a total of 68 positive surveillance cultures, 33 (49%)
were rectal, 17 (25%) pharynx, 16 (23%) EA, and 2 (3%)
urine. Rectal screening identified 77% of colonized
patients upon admission, 91% after 1 week of ICU stay,
and nearly 100% thereafter.
PA genotyping
During the entire ICU stay we found 20 clonal ERIC-
PCR genotypes (among 18 patients) and 11 unique
genotypes from 9 patients (two patients had 2 isolates).
In the clonal analysis we included cases that were
excluded because of being positive on late screening.
Overall, the clonal structure was diverse. There were
no dominant strains (related to many patients or to clin-
ical cultures). Twelve patients (patients 2, 4, 5, 7, 8, 10,
12, 14, 15, 16, 17, 18 in Fig. 2) had >1 screening culture
(on a following week) available for genotypic analysis
(range, 1 to 10 isolates per patient). In 11 of these
patients (92%) a serial identical isolate was identified on
the following week (all except patient 12, in which the
same genotype O was indeed found but only after 2 and
4 weeks, Fig. 2).
Fig. 1 Study population
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Table 2 P. aeruginosa colonization during ICU stay in 4 screening sites
Any site (%) Pharynx (%) EA (%) Urine (%) Rectum (%)
Admission screening (n = 38) 13 (34) 3 (23) 6 (46) 1 (7) 10 (77)
Week 1 (n = 21) 11 (52) 5 (45) 3 (27) 0 (0) 10 (91)
Week 2 (n = 8) 6 (75) 4 (66) 3 (50) 0 (0) 6 (100)
Week 3 (n = 7) 5 (71) 4 (80) 4 (80) 1 (20) 4 (80)
Week 4 (n = 4) 2 (50) 0 (0) 0 (0) 0 (0) 2 (100)
Week 5 (n = 2) 1 (50) 1 (100) 1 (100) 0 (0) 1 (100)
Week 6 (n = 1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ICU intensive care unit, EA endotracheal aspirate
Table 1 Patient characteristics according to P. aeruginosa carriage status on ICU admission




P (OR, 95% CI)
Age mean (range) 70.3 (15-96) 65.6 (15-96) 79.3 (45-94) 0.0039
Age over 70 years 22 (58%) 11 (44%) 11 (84%) 0.035 (7, 1.2-38.3)
Sex
Male 22 (58) 16 (64) 6 (46) 0.52
Female 16 (42) 9 (36) 7 (54) 0.52
LTCF residency 3 (8) 0 3 (23) 0.033 (17, 0.8-358)
APACHE II score, mean (range) 21.4 (10-42) 21.0 (10-42) 22.1 (14-34) 0.66
Days in hospital until ICU admission, mean (range) 3.7 (0-22) 3.7 (0-22) 3.7 (0-11) 0.98
Hospitalization in the last 90 days 19 (50) 11 (44) 8 (61) 0.49
Surgery in the last 30 days 14 (37) 8 (32) 6 (46) 0.48
Antimicrobials in the last 90 days 17 (45) 12 (48) 5 (38) 0.73
Prior PA in last 90 days 3 (8) 1 (4) 2 (15) 0.26
ICU LOS, mean (range) 15 (3-62) 10.6 (3-39) 23.7 (5-62) 0.0338
Hospital LOS, mean (range) 28 (6-88) 25 (6-80) 33.7 (10-88) 0.14
Ventilation days in ICU, mean (range) 17.3 (0-88) 12.8 (0-79) 26 (0-88) 0.16
COPD 11 (29) 7 (28) 4 (31) 1
IHD 15 (39) 8 (32) 7 (54) 0.29
CHF 14 (37) 7 (28) 7 (54) 0.16
Past CVA 9 (24) 6 (24) 3 (23) 1
CRF 8 (21) 5 (20) 3 (23) 1
Immunosuppression 4 (10) 4 (16) 0 0.27
Dementia 4 (10) 1 (4) 3 (23) 0.1
Active malignancy 4 (10) 3 (12) 1 (7) 1
DM type 2 15 (39) 14 (56) 1 (7) 0.005 (0.06, 0.007-0.58)
Tracheostomy in ICU 12 (31) 6 (24) 6 (46) 0.27
ICU death 5 (13) 2 (8) 3 (23) 0.31
Overall death 13 (34) 8 (32) 5 (38) 0.7
All numbers represent patients (percent), unless specified otherwise. LTCF long term care facility, APACHE, acute physiology and chronic health evaluation, ICU
Intensive care unit, PA P. aeruginosa, LOS length of stay, COPD chronic obstructive pulmonary disease, IHD ischemic heart disease, CHF congestive heart failure,
CVA cerebrovascular accident, CRF chronic renal failure, DM diabetes mellitus, VAP ventilator associated pneumonia, CLABSI central line associated blood stream
infection, CAUTI catheter associated urinary tract infection, OR odds ratio, CI confidence interval
Cohen et al. Antimicrobial Resistance and Infection Control  (2017) 6:7 Page 4 of 9
Clonal persistence vs. replacement in sequential
screening
Rectum screening: 10 patients had at least 1 sequential
rectal screening culture available for typing. In 9 of these
(90%) the same clone persisted at least once (range 1–3
weeks). In 3 patients (30%) other strains appeared.
Pharynx screening: 5 patients had at least 1 sequen-
tial pharynx screening culture available for typing and
in 4 (80%) the same clone persisted at least once (range
1–3 weeks).
AE screening: 4 patients had at least 1 sequential
AE screening culture available for typing and in 3
(75%) the same clone persisted at least once (range
1–3 weeks). Cross-overs between sites and strains
occurred (Fig. 2).
Calculated together, in 16 out of 19 (84%) of patients
in which a sequential same-site screening cultures were
available for typing, the same clone persisted. Clonal
persistence was evident in all screening sites, but was
most prominent in the rectum (90% vs. 80% and 75% in
the pharynx and AE, respectively). Cross-overs between
sites and strains occurred (Fig. 2).
In 5 patients a spread from the original site of
identification to other screening sites was evident
(Fig. 2). On 3 occasions the same genotype (B, C, S)
was identified in different patients, indicating cross
transmission.
Clinical impact of PA isolation in the ICU
Thirteen patients (29%) were diagnosed with PA infection:
10 with VAP, 4 with SSI and 1 with bloodstream infection.
Ten additional patients (22%) acquired PA colonization
without infection.
Patients colonized with PA on admission were at a
higher risk of PA-related clinical infection, compared with
patients who were PA-negative on admission [8/13 (62%)
vs. 1/25 (4%), hazard ratio = 14.65, CI (3.07–47.39), p =
0.0002], and for PA-related VAP [hazard ratio = 7.381, CI
(1.39–36.41), p = 0.0047], Fig. 3). PA-colonized patients
also had significantly longer mean stay in the ICU (23.7
days versus 10.6 days; p = 0.033, Table 1). None of the 22
patients with repeated negative screening had a positive
clinical culture with PA throughout their ICU stay.
Genotyping was performed on 17 clinical isolates from
12 patients (patients 1, 2, 4, 6, 7, 8, 12, 13, 15, 16, 17, 18;
Fig. 2). Sixteen (94%) clinical strains were related to strains
found concurrently or previously on screening cultures
from the same patient and none were unique (Fig. 2,
Table 3). The one exceptional clinical isolate (C2 from pa-
tient 4) was not unique since it was found in the screening
cultures of patient 5). In 6 patients (50%) the clinical PA
isolate could have been predicted from the screening cul-
tures between 1 and 4 weeks earlier (genotypes A, K2, G,
O, S1, S2); and in the other 6 patients the identification by
screening occurred on the same week (genotypes B1, D, I,
Fig. 2 P. aeruginosa ERIC-PCR strains among 23 positive patients
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P, R, U). However, six patients (50%) had screening PA iso-
lates that were different from a concurrent or subsequent
clinical PA strain (patients 2, 4, 7, 12, 16, 17). The accur-
acy of (any site) surveillance cultures to predict the same
genotype cultivation in a clinical sample was 76% (36/47),
75% (43/57) and 72% (45/62) when obtained on the same
week or within 1 week before, 2 week before and through-
out the ICU stay, respectively.
Table 4 shows the correlation of the site-specific
screening culture with the infective strain according to
the different diagnoses. Among 8 patients with VAP
(who had clinical AE cultures available for typing), iden-
tical surveillance cultures were recovered from EA in 7
(87%), from the pharynx in 6 (75%), and from the rec-
tum in 4 (50%). Among 4 patients with SSI, identical
surveillance cultures were recovered from EA, pharynx
and rectum in 2 patients (50%) each.
Discussion
We used systematic sequential screening to define the
dynamics of PA colonization and infection at a general
ICU. In a non-outbreak setting, we found a highly
diverse population of patient-unique PA strains. Strains
were often site-specific and site-persistent, particularly
with regards to rectal colonization, but could also dis-
tribute between body sites, and be replaced frequently.
A positive screening culture for PA was associated with
an increased risk of PA related infection: there was a
50–70% likelihood of subsequent clinical infection with
the same strain, depending on the timing and site of
screening. Importantly, we found that when adequate in-
fection control standards are maintained, repeated nega-
tive multi-site screening results were associated with a
very low rate of subsequent clinical infection with PA.
A third of our patients were carriers of PA on admission
to the ICU (26% rectal, 16% EA and 8% pharyngeal car-
riage). Bonten et al. reported similar figures (34%) along
with striking similarities regarding the relative importance
of the sites of screening: the gastrointestinal being the most
sensitive (24% positivity), and pharynx and EA being posi-
tive in only 9% and 7%, respectively [3]. In a more recent
study, Zorilla et al. reported similar findings (27% PA
colonization on admission) [21]. Advanced age and prior
hospital stay were risk factors for PA colonization on
admission. Similarly, we found advanced age and residence
in a LTCF as significant risk factors. Surprisingly, diabetes
mellitus was associated with a low rate of PA colonization
on ICU admission. In line with others [1, 22], we found that
colonization often preceded infection. Specifically, patients
colonized upon admission had a 14.65-fold risk of develop-
ing infection as compared with non-colonized patients.
Early and accurate antibiotic coverage in patients
developing VAP in the ICU is critical to improve patient
outcomes [23, 24], but the increasing rates of multidrug
resistant (MDR) organisms (including PA) in ICU and
non-ICU patients pose an obstacle for appropriate empiric
therapy. Accurate prediction of antimicrobial resistance
patterns of organisms causing VAP by using surveillance
cultures in ICUs has been a matter of an ongoing debate
in the literature. A recent systematic review and a meta-
Fig. 3 Kaplan-Meier survival curves, comparing PA-related outcomes between positive and negative patients on admission
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analysis found high accuracy of surveillance cultures, with
pooled sensitivities of up to 0.75 and specificities up to
0.92 in culture-positive VAP [25]. Our results support the
predictive value of surveillance cultures: among patients
who developed VAP, screening the EA or the pharynx
accurately predicted the VAP-related strain in 75–87% of
episodes. SSI-related strains were predicted by EA and
pharynx screening in 50% of cases.
None of the patients who had persistently negative
surveillance cultures had subsequent recovery of PA
from clinical cultures. Similar findings were reported in the
meta-analysis cited [25]. Hence, screening two sites weekly
with negative results can provide reassurance for the phys-
ician not to initiate empirical anti-pseudomonal antibiotics
in patients with suspected VAP or SSI, which are among
the most frequent infections in critically ill patients. This
finding may have implications for antibiotic stewardship, as
it provides an evidence-based framework for limiting the
use of wide-spectrum antibiotics in the ICU.
The current study is unique in providing a longitudinal
assessment of PA colonization dynamics in multiple body
sites throughout the ICU stay. Recently, Zorrilla et al. [1]
found high rates (87%) of genotypic concordance between
rectal surveillance cultures and infecting strains of PA. Our
Table 3 Concordance between screening and clinical ERIC-PCR strains
Patient number Screening culture strain Site of screening Clinical culture strain Clinical culture site Timing between screen
and clinical culture
Correlated cases 1 B1 EA, P B1 Wound Same week
2 A Rc A EA Same week
Rc Urine 1 week
EA, P, Rc Same week
4 D2 Rc D1 Abdomen Same week
K1 Rc K2 EA 2 weeks
B2 Rc B2 Urine Same week
6 E2 EA, P E1 EA Same week
7 I1, I2 EA, P I1 EA Same week
8 G Rc G Blood 3 weeks
EA, P, Rc 2 weeks
EA, P, Rc 1 week
EA, P, Rc Same week
12 O Rc O Wound 4 weeks
Rc 2 weeks
13 P EA, P, Rc, U P Wound Same week
Urine Same week
15 R EA R EA Same week
16 S1 EA, P S1 EA 2 weeks
P 1 week
EA, P Same week
17 S2 P S2 EA 1 week
EA, P Same week
18 U EA U EA Same week
Uncorrelated cases 2 Sg P A EA Same week
Urine 1 week
4 D2 Rc C2 Wound 1 week and same week
B2 Rc K2 EA Same week
7 Sg Rc I1 EA Same week
12 Sg Rc O Wound Same week
16 T Rc S1 EA Same week
17 W Rc S2 EA Same week
A-W – ERIC-PCR strain (a number denotes a clone subtype), Sg unique strain, EA endotracheal aspirate, P pharynx, Rc – rectum, U urine
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results underscore the limitations of rectal screening for
predicting respiratory strains, as further demonstrated in a
study performed among hematopoietic stem cell recipients
[26]. The high efficacy of lower airways screening to predict
the strains that caused VAP is consistent with results of
previous studies [3, 10].
The limitations of this study are the relatively small
number of patients in a single center setting. Screening
was limited to PA colonization, whereas in clinical prac-
tice empiric antimicrobial therapy often targets other
MDR bacteria such as MRSA, MDR-Acinetobacter spp.
and ESBL-producing Enterobacteriaceae. From a prac-
tical perspective, screening 3 body sites for PA only, may
be expensive and labor intensive, and will miss other im-
portant causes of VAP and SSI. Another limitation is
that antimicrobial susceptibility data of all screening
strains was not available for comparison. Therefore, the
utility of screening cultures to predict the susceptibility
patterns of clinical PA strains remains to be established.
Conclusions
In this study we showed that in a non-outbreak setting
of ICU, most strains were patient-unique, endogenous in
origin, and cross contamination was rare. Colonization
on admission was a significant risk factor for the devel-
opment of infection with PA. Detection of PA on sur-
veillance cultures may serve as a good predictor of PA
clinical infection and also of the infecting clone, while
negative screening is an excellent negative predictor for
clinical infection. VAP-related strains are better pre-
dicted by upper airways screening than rectal screening.
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